NCT02227732

Brief Summary

The purpose of this study is to determine whether a new catheter is safe and effective in treating malignant pleural effusions.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2014

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2014

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

July 8, 2014

Completed
2 months until next milestone

First Posted

Study publicly available on registry

August 28, 2014

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2015

Completed
Last Updated

November 26, 2025

Status Verified

November 1, 2025

Enrollment Period

1.1 years

First QC Date

July 8, 2014

Last Update Submit

November 25, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Device -related safety and the number of adverse events.

    28 days post catheter insertion

Secondary Outcomes (3)

  • pleurodesis success

    14 days

  • Pleurodesis success

    28 days

  • pleurodesis success

    60 days

Other Outcomes (5)

  • Breathlesness

    14, 28, 60 days

  • Chest Pain

    14, 28, 60 days

  • Time to pleurodesis

    14, 28, 60 days

  • +2 more other outcomes

Study Arms (1)

New Indwelling Pleural Catheter

OTHER
Device: New Indwelling Pleural Catheter

Interventions

Placement of an indwelling catheter in the pleural space. Drainage of effusions until resolution.

New Indwelling Pleural Catheter

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject is ≥ 18 years old.
  • Subject has a symptomatic malignant pleural effusion requiring intervention. For an effusion to be defined as malignant, at least one of the following must be true:
  • There is histocytological confirmation of pleural malignancy
  • The effusion is an exudate (as per Light's criteria) in the context of histocytologically proven malignancy elsewhere, with no other clear cause for fluid identified
  • Subject has a history of at least one ipsilateral pleural effusion causing dyspnoea that responded to thoracentesis where the lung expanded and the dyspnoea was relieved.
  • Subject is willing and able to provide written informed consent.
  • Subject is willing and able to meet all study requirements, including attending follow-up visits or receiving trial-related telephone calls.
  • There is sufficient fluid on thoracic ultrasound to allow safe insertion of an indwelling pleural catheter
  • Negative pregnancy test if appropriate

You may not qualify if:

  • Subject has significant trapped lung (\>20%), or a proximal bronchial obstruction which is likely to lead to trapped lung.
  • Subject has a Karnofsky score of less than 50, or a WHO/ECOG performance status of 3\* or more.
  • Subject is pregnant, planning to become pregnant, or is lactating.
  • Subject has a history of empyema.
  • Subject has a history of chylothorax.
  • Subject has an uncorrected coagulopathy.
  • Subject is allergic to device materials.
  • Subject has evidence, in the opinion of the Chief Investigator, of either on-going systemic or pleural infection.
  • Subject has had a lobectomy or pneumonectomy on the side of the effusion.
  • Subject has undergone a previous attempt at pleurodesis which has failed.
  • Subject has previously been diagnosed with a serious immunodeficiency disorder.
  • Subject has bilateral pleural effusions, with both being at least moderate in size (greater than 1/3 of the hemithorax on chest x-ray).
  • Subject has evidence of fluid loculation such that attempts at pleurodesis are likely to be futile.
  • Subject has a mediastinal shift of ≥2cm toward the side of the effusion.
  • Subject is receiving concurrent intrapleural chemotherapy or radiation therapy to the ipsilateral chest.
  • +3 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Southmead Hospital - Academic Resporatory Unit

Westbury on Severn, Bristol, BS10 5NB, United Kingdom

Location

MeSH Terms

Conditions

Pleural Effusion, Malignant

Condition Hierarchy (Ancestors)

Pleural NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsPleural EffusionPleural DiseasesRespiratory Tract Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 8, 2014

First Posted

August 28, 2014

Study Start

April 1, 2014

Primary Completion

May 1, 2015

Study Completion

May 1, 2015

Last Updated

November 26, 2025

Record last verified: 2025-11

Locations